IOM releases modeling software for vaccine prioritization

The Institute of Medicine (IOM) has created software to help researchers choose where to allocate vaccine R&D dollars. Using World Health Organization (WHO) data, the software builds models to estimate the lives a vaccine could save and the likelihood of it being profitable. Article

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.